HRT and heart disease: Problems and prospects

Maturitas

Volumn 47, Issue 4, 2004, Pages 255-258

  Maas, Angela H E M ^a   Van Der Graaf, Yolanda ^b   Van Der Schouw, Yvonne T ^b   Grobbee, Diederick E ^b  

^a Isala Klinieken ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Prevention

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; STATIN;

ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM LESION; HEART DISEASE; HEART REINFARCTION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MENOPAUSE; RECURRENT DISEASE; THROMBOGENICITY; UNSTABLE ANGINA PECTORIS; VASCULAR LESION;

CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE;

EID: 1942504182     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.10.012     Document Type: Conference Paper

References (30)

1. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group (see comments). JAMA. 280:1998;605-613.
2. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E.et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 343:2000;522-529.
3. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. J. Med. 345:2001;1243-1249.
4. Heckbert S.R., Weiss N.S., Koepsell T.D., Lemaitre R.N., Smith N.L., Siscovick D.S.et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch. Intern. Med. 157:1997;1330-1336.
5. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
6. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann. Intern. Med. 135:2001;1-8.
7. Heckbert S.R., Kaplan R.C., Weiss N.S., Psaty B.M., Lin D., Furberg C.D.et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch. Intern. Med. 161:2001;1709-1713.
8. Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
9. Kleerekoper M. Lessons from the skeleton: was the women's health initiative (WHI) a primary prevention trial? Osteoporos. Int. 13:2002;685-687.
10. Herrington D.M., Espeland M.A., Crouse J.R. III, Robertson J., Riley W.A., McBurnie M.A.et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler. Thromb. Vasc. Biol. 21:2001;1955-1961.
11. Mikkola T.S., Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53:2002;605-619.
12. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63.
13. Langer R.D. Hormone replacement and the prevention of cardiovascular disease. Am. J. Cardiol. 89:2002;36E-46E.
14. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health. 19:1998;55-72.
15. Humphrey L.L., Chan B.K., Sox H.C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann. Intern. Med. 137:2002;273-284.
16. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA. 288:2002;872-881.
17. Hodis H.N., Mack W.J., Lobo R.A., Shoupe D., Sevanian A., Mahrer P.R.et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135:2001;939-953.
18. Shlipak M.G., Angeja B.G., Go A.S., Frederick P.D., Canto J.G., Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 104:2001;2300-2304.
19. O'Keefe J.H. Jr., Kim S.C., Hall R.R., Cochran V.C., Lawhorn S.L., McCallister B.D. Estrogen replacement therapy after coronary angioplasty in women. J. Am. Coll. Cardiol. 29:1997;1-5.
20. Abu-Halawa S.A., Thompson K., Kirkeeide R.L., Vaughn W.K., Rosales O., Fujisi K.et al. Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am. J. Cardiol. 82:1998;409-413.
21. Khan M.A., Liu M.W., Singh D., Pal A., Chio F.L., Lawson D.et al. Long-term (three years) effect of estrogen replacement therapy on major adverse cardiac events in postmenopausal women after intracoronary stenting. Am. J. Cardiol. 86:2000;330-333.
22. Sullivan J.M., El Zeky F., Vander Z.R., Ramanathan K.B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am. J. Cardiol. 79:1997;847-850.
23. Hodis H.N., Mack W.J., Azen S.P., Lobo R.A., Shoupe D., Mahrer P.R.et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. 349:2003;535-545.
24. Waters D.D., Alderman E.L., Hsia J., Howard B.V., Cobb F.R., Rogers W.J.et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 288:2002;2432-2440.
25. Herrington D.M., Vittinghoff E., Lin F., Fong J., Harris F., Hunninghake D.et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 105:2002;2962-2967.
26. Grady D., Hulley S.B. Postmenopausal hormones and heart disease. J. Am. Coll. Cardiol. 38:2001;8-10.
27. Hemminki R., McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet. 355:2000;566-569.
28. Alexander K.P., Newby L.K., Hellkamp A.S., Harrington R.A., Peterson E.D., Kopecky S.et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J. Am. Coll. Cardiol. 38:2001;1-7.
29. The ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002; 360: 2001-08.
30. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L.et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349:2003;523-534.